Meropenem Anfarm

Meropenem, the active ingredient in Meropenem Anfarm, is a carbapenem antibiotic presented as a sterile powder for intravenous infusion for IV use. It treats severe bacterial infections such as complicated intra‑abdominal infections, complicated urinary tract infections, bacterial meningitis, sepsis, and hospital‑acquired pneumonia in adult patients.

GNH USA supplies Meropenem Anfarm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Meropenem is a broad‑spectrum carbapenem used for serious bacterial infections across several organ systems.

- Complicated intra‑abdominal infections: provides bacterial eradication leading to clinical cure. - Complicated urinary tract infections: eliminates resistant uropathogens and resolves infection. - Bacterial meningitis: penetrates the cerebrospinal fluid to treat meningitic pathogens. - Severe sepsis and septic shock: rapidly reduces bacterial load to support hemodynamic recovery. - Hospital‑acquired and ventilator‑associated pneumonia: targets multidrug‑resistant organisms causing pneumonia.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: may be self‑limited or indicate altered gut flora. - Headache: transient and usually resolves without intervention. - Infusion site phlebitis: local irritation at the IV site.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Seizures: especially in patients with renal impairment or high plasma concentrations. - Clostridioides difficile‑associated colitis: severe diarrhea due to disruption of normal intestinal microbiota.

Before initiating therapy, consider the following precautions: - Renal function assessment: adjust dose in patients with impaired clearance. - Hepatic function monitoring: observe liver enzymes during prolonged treatment. - History of seizures: use with caution as the drug may lower seizure threshold. - Concurrent valproic acid therapy: monitor for increased neurotoxicity. - Pregnancy and lactation: evaluate risk‑benefit ratio before use. - Store at 2‑8°C: keep refrigerated, protect from light, do not freeze.

Meropenem may interact with several agents; monitor accordingly.

Major Interactions (Avoid): - Valproic acid: increased risk of neurotoxicity. - Carbapenem‑resistant organisms: reduced antimicrobial efficacy. - Probenecid: may raise meropenem plasma concentrations. - High‑dose aminoglycosides: additive nephrotoxicity.

Moderate Interactions (Monitor Closely): - Loop diuretics: watch renal function and electrolyte balance. - Warfarin: monitor INR for potential anticoagulation changes. - Anticonvulsants (e.g., phenytoin): may lower seizure threshold.